#India #Oligonucleotide Synthesis #Co-Diagnostics #CoSara Diagnostics #Ranoli

Co-Diagnostics and CoSara Diagnostics Unveil New Facility

On December 11, 2024, Co-Diagnostics, Inc. and CoSara Diagnostics Pvt. Ltd. will inaugurate an innovative oligonucleotide synthesis facility in Ranoli, India. This event marks a significant chapter in the collaboration between these companies, aimed at enhancing healthcare in India.

Supporting Make in India Initiative

The new facility is a critical step in supporting India’s “Make in India” initiative, focusing on the domestic production of Co-Diagnostics’ patented Co-Primers® chemistry. This advancement is designed to meet the growing demand for laboratory-based PCR diagnostic tests while ensuring that the technologies underpinning these tests are produced locally.

The establishment of this facility aims to remove barriers to healthcare access in one of the world’s largest markets, paving the way for greater availability of diagnostic tools. According to Mohal Sarabhai, CEO of CoSara Diagnostics, the future will likely see further expansion efforts, including manufacturing capabilities for additional products like the Co-Dx PCR Pro instrument and diagnostic tests for various diseases, such as tuberculosis (TB) and human papillomavirus (HPV).

Addressing Global Health Concerns

The timing of this facility's launch also resonates deeply with public health concerns. The World Health Organization (WHO) reported that tuberculosis remains a global health crisis, affecting millions worldwide. In fact, 10.8 million people were reported to have fallen ill from the disease in 2023, marking TB as one of the most significant causes of death globally from a single infectious agent.

With the innovative Co-Primers® technology, both Co-Diagnostics and CoSara aim to improve the efficiency and accessibility of diagnosing such diseases. This facility embodies the companies’ commitment to transforming the healthcare landscape by making high-quality diagnostic solutions more readily available in India.

Milestone Event

The inauguration event is poised to gather notable attendees, including government representatives and leaders from various non-governmental organizations (NGOs). This collaborative spirit is essential as the new facility will not only enhance Co-Diagnostics' operational capabilities but is also seen as a milestone in their mission to bridge gaps in infectious disease diagnostics on a global scale.

Dwight Egan, CEO of Co-Diagnostics, expressed pride in this new chapter, indicating that the facility is a testament to the foresight demonstrated in 2017 when Co-Diagnostics partnered with Synbiotics Ltd. to form CoSara. The advancements in manufacturing efficiency brought about by the new facility are expected to mirror the success that Co-Diagnostics has achieved in developing its state-of-the-art diagnostic technologies.

The Future of Healthcare in India

Looking ahead, the potential development of a robust healthcare infrastructure in India is promising. By synthesizing Co-Primers in-house, Co-Diagnostics is set to enhance its manufacturing efficiency and ultimately bring its newly developed PCR testing platform to the market. While regulatory approvals are underway and commercialization is on the horizon, the cooperative efforts between Co-Diagnostics and CoSara are well-positioned to introduce innovative healthcare solutions to one of the most populous countries in the world.

In summary, the inauguration of this oligonucleotide synthesis facility not only symbolizes a technological and operational advancement for Co-Diagnostics and CoSara but also represents a broader commitment to improving global health, particularly in resource-rich markets like India. The companies express gratitude towards their partners and stakeholders who have contributed to making this vision a reality. For those interested in participating in the ribbon-cutting event, invitations can be arranged through the designated contact.